Demand for Precise Medical Care and Need for Scalable Manufacturing Solutions Fueling the Antibody Contract Manufacturing Market Growth
Rockville, Dec. 04, 2023 (GLOBE NEWSWIRE) -- The global Antibody Contract Manufacturing Market is projected reach a valuation of US$ 6.1 billion in 2024. The market is forecasted to expand at an impressive 13.1% CAGR from 2024 to 2034, according to a recent market research analysis by Fact.MR, a market research and competitive intelligence provider.
Growing need for customized treatment and a surge in biopharmaceutical R&D are projected to propel the growth of the global antibody contract manufacturing market. The process of contract manufacturing involves assigning the production of monoclonal antibodies to specialist businesses that have access to advanced equipment and expertise. Since monoclonal antibodies are increasingly being utilized to treat a wide range of conditions, including cancer, autoimmune disorders, and infectious diseases, the market is exhibiting tremendous growth.
For More Insights into the Market, Request a Sample of this Report:
Key Segments of Antibody Contract Manufacturing Industry Research Report
By Product Type
By Expression System
By Company Size
By Scale of Operation
By End User
Demand for antibody contract manufacturing is also booming due to the customization of antibodies to target specific antigens and the growing preference for biologics over conventional small-molecule medications.
Key Takeaways from Market Study
The global antibody contract manufacturing market is projected to expand at a high-value CAGR of 13.1% through 2034.
North America is estimated to hold a market share of 34.8% in 2024.
The monoclonal antibodies segment is set to account for a market share of 89.3% in 2024.
Demand for antibody contract manufacturing is projected to reach a market value of US$ 20.85 billion by the end of 2034.
East Asia is predicted to account for a market share of 27.4% in 2024.
The mammalian expression system segment is predicted to expand at a CAGR of 13.3% through 2034.
"The antibody contract manufacturing market is experiencing a transformative phase driven by technological advancements and strategic collaborations. This market not only supports pharmaceutical companies in accelerating drug development but also ensures the timely and cost-effective production of high-quality antibodies,” says a Fact.MR analyst.
Growing Emphasis on Development of Therapeutic Molecules Derived from Biological Sources
The pursuit of novel biopharmaceuticals involves extensive exploration into the human genome, deciphering intricate biological pathways, and identifying specific targets for treatment. Researchers meticulously engineer biological molecules like monoclonal antibodies, peptides, and recombinant proteins to create tailored therapies capable of precise interactions within the body. This precision medicine approach addressing individual patient variations marks a significant departure from traditional small molecule drugs, as it offers heightened efficacy and reduced adverse effects.
Research and development in the field of biopharmaceuticals continue to evolve owing to advancements in genetic engineering, cell culture methods, and bioprocessing approaches. The development of advanced methods of analysis has made it possible for scientists to delve deeper into the complex processes that underlie illnesses, which has aided in the discovery of new therapeutic targets. Innovation in biopharmaceutical R&D not only pushes the boundaries of scientific knowledge, but also has the potential to completely transform patient care by providing tailored, effective treatments for a wide range of diseases, including cancer, autoimmune disorders, and rare genetic conditions.
Get Customization on this Report for Specific Research Solutions:
Value Projection (2034)
USD 20.85 Billion
Growth Rate (2024-2034)
No. of pages
No. of Tables
No. of Figures
The competitive landscape of the antibody contract manufacturing market is characterized by key players vying for a substantial market share through innovation, capacity expansion, and strategic collaborations. Prominent companies in this market include Lonza Group, Catalent, Inc., Samsung Biologics, Boehringer Ingelheim, and Thermo Fisher Scientific.
Intense competition is driving companies to prioritize differentiation strategies, such as providing comprehensive services across the antibody manufacturing value chain, encompassing cell line development, process optimization, and regulatory compliance.
In July 2023, TVM Capital Life Science and Tillotts Pharma jointly invested US$ 28 million in Mage Biologics, aiming to advance the development of an innovative oral antibody therapy for ulcerative colitis.
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the antibody contract manufacturing market for 2018 to 2023 and forecast statistics for 2024 to 2034.
The study divulges essential insights into the market based on product type (monoclonal antibodies, antibody fragments, polyclonal antibodies, others), expression system (mammalian, microbial), company size (small, mid-sized, large, very large), scale of operation (preclinical, clinical, commercial), and end user (biopharmaceutical companies, research laboratories, others), across six major regions of the world (North America, Latin America, Europe, East Asia, South Asia & Oceania, and MEA).
Checkout More Related Studies Published by Fact.MR Research:
Antibody Fragments Market: The antibody fragments market is currently valued at USD 7.56 billion and is expected to grow at a compound annual growth rate (CAGR) of 5.9% during the forecast period. The market is to reach USD 13.41 Billion by 2032.
Antibody Drug Conjugates Contract Market: The global antibody drug conjugate contract market demand is anticipated to be valued at US$ 9.2 Billion in 2022, forecast a CAGR of 15.5% to be valued at US$ 38.8 Billion from 2022 to 2032.
Antibody Library Technology Market: The global antibody library technology market size is estimated at US$ 165.8 million for 2024 and is projected to reach a valuation of US$ 246.5 million by the end of 2034, advancing at a CAGR of 4% over the next ten years (2024 to 2034).
Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning. With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.